Please login to the form below

Not currently logged in
Email:
Password:

BMS-986205

This page shows the latest BMS-986205 news and features for those working in and with pharma, biotech and healthcare.

BMS pulls IDO inhibitor trials as Incyte-prompted rout gathers pace

BMS pulls IDO inhibitor trials as Incyte-prompted rout gathers pace

BMS pulls IDO inhibitor trials as Incyte-prompted rout gathers pace. Suspends enrolment in BMS-986205 trials for NSCLC and head and neck cancer. ... Bristol-Myers Squibb hammered another nail in the coffin of IDO1 as a drug target in immuno-oncology

Latest news

  • BMS boosts immuno-oncology with $2.3bn IFM buy BMS boosts immuno-oncology with $2.3bn IFM buy

    BMS boosts immuno-oncology with $2.3bn IFM buy. Boston-based group will operate as a subsidiary of BMS. ... The big pharma has steadily added to its portfolio with a stream of candidates targeting molecules such as CD137 (urelumab), IDO (BMS-986205), and

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Dovetail

We're award-winning joint working specialists. We help our clients to transform healthcare through effective collaboration, and deliver work to feel...

Latest intelligence

Ali Frederic Ben-Amor
Tackling a formidable foe
Ali Frederic Ben-Amor tells how Merck is taking the fight to multiple sclerosis...
Geoff
Cancer care – the power of new technologies
With patient numbers set to soar, how can we make a difference?...
image 1
Redefining communications excellence
How to be heard in today’s multichannel, multistakeholder, multimedia world...

Infographics